• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Report: Dexcom in talks to acquire Insulet

May 23, 2022 By Sean Whooley

Dexcom Insulet Omnipod 5 G6Major players in the diabetes space could join forces as Dexcom (Nasdaq:DXCM) is reportedly in discussions to acquire Insulet (Nasdaq:PODD).

Bloomberg reported today that people “with knowledge of the matter” have said talks are ongoing over a potential acquisition and even said an agreement could be reached “in the coming weeks.” Bloomberg said its sources preferred to remain anonymous because the information is private and both companies declined to offer comment.

No potential financial figures related to any acquisition discussions were revealed in the report.

San Diego-based Dexcom, a leader in continuous glucose monitoring (CGM) technology, and Insulet, an Acton, Massachusetts-based automated insulin delivery technology maker, are not new to one another. The two companies partnered in early 2020 to use Dexcom’s CGM with Insulet’s wearable pump and have since worked together on next-generation technologies, as Insulet’s recently FDA-cleared Omnipod 5 automated insulin delivery system uses Dexcom’s G6 CGM.

Officials from both companies have previously said that once Dexcom’s next-generation G7 CGM receives FDA approval — which could come as soon as next month with current expectations of a regulatory nod after the American Diabetes Association Scientific Sessions —  work will be done to integrate it into the Omnipod 5 platform.

The news of a potential acquisition comes at an interesting time. Insulet announced earlier this month that CEO Shacey Petrovic was stepping down due to personal reasons. She will be succeeded by ResMed executive Jim Hollingshead, beginning June 1.

BTIG analyst Marie Thibault wrote in a report that such a deal would be surprising as the timing is unfavorable with Dexcom’s stock price currently near a two-year low (down 40% year-to-date) and Insulet down 24% in 2022.

Additionally, the analyst believes an acquisition would appear to be a detour from Dexcom’s focus on growth in the non-intensive type 2 diabetes market, while it could represent a departure from open innovation in diabetes tech and — she stressed it is BTIG’s “own supposition” — it could result in fewer choices for patients.

“We do not typically write notes in response to such reports, but such a potential deal, if it were to happen, would likely be transformative and impactful to the diabetes technology landscape,” Thibault wrote. “We think the potential deal would make sense in some ways, as it would unite two fast-growing major players entering new product cycles that are both expected to grow 20+% over the next few years. … There would likely be synergies since the companies sell into the same clinician call points, have relatively similar margin profiles, and we believe they share similar philosophies on commitment to R&D, marketing, and education. We think the merits of a potential deal, if announced, would likely be debated by investors.”

PODD shares shot up more than 5%, to $214.71 apiece, in morning trading, while DXCM shares took a hit, down more than 8% to $295.38 apiece. MassDevice and DDBN‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was down slightly.

Filed Under: Auto-injectors, Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Mergers & Acquisitions, Patient Monitoring, Technology Tagged With: Dexcom, Insulet

IN CASE YOU MISSED IT

  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes
  • Study backs Tandem automated insulin delivery in pregnant women with type 1 diabetes
  • Data backs Medtronic MiniMed 780G for type 2, children as company seeks expanded indications
  • Abbott could pave new roads in diabetes management with dual sensor on the horizon

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS